Novartis chooses internal replacement for US pharma president role

Bulto is currently the head of Novartis’ US immunology, hepatology and dermatology franchise and has been an exec at the Swiss pharma company for 14 years.

GSK hires Merck KGaA exec to lead US pharma business

Prior to taking up the Latin America position, Martinez-Davis spent two years as global head of the oncology franchise at Merck KGaA, having landed that position on the strength of

Leiden reassures on key role at Vertex

Soon after followed the approval of the company's first CF treatment, Kalydeco, which signalled the beginning of a highly profitable franchise. ... William Blair analysts forecast that Vertex's CF franchise will peak at sales of $10.2bn, and the company

Tecfidera successor’s side-effect profile boosts Biogen

But analysts unconvinced that patients will switch. Biogen’s flagship multiple sclerosis franchise has been given a major boost thanks to safety data from its follow-on to blockbuster Tecfidera. ... Biogen had been hoping to lessen its reliance on its

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]